Professor N M Bleehen (Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ) Chemotherapy of Osteosarcoma The previous contributions have indicated the limits which conventional surgical and radiotherapeutic approaches have reached in the management of osteosarcoma. Considerable hope has been raised by the recent development of chemotherapy regimes which produce a significant number of responses in patients with metastatic disease which until recently has been regarded as resistant to drug therapy (reviewed by Friedman & Carter 1972) .
Amongst the most promising regimes, high doses of methotrexate followed by citrovorum factor (HDMTX) were reported by Jaffe (1972) , and adriamycin either alone or in combination with 5-(3, 3-dimethyl-l-triazeno) imidazole-4carboxamide (DTIC), as reported by Gottlieb (1974) , have been shown to produce useful responses. Thus in the latter report, there were 13 complete or partial responses out of 31 patients treated by adriamycin and DTIC. This is in contrast to the report by Cortes et al. (1975) using adriaMycin alone, in which only 2 partial remissions were obtained in 26 patients with unresectable or metastatic disease. Rosen et al. (1974) have described a regime combining HDMTX combined with adriamycin. Out of 13 children with metastatic disease, 7 showed a significant response for longer than one month and there was additional symptomatic relief in some of the nonresponders.
As a result of these observations in established metastatic disease, several groups of workers have investigated the value of adjuvant chemotherapy forthe primary surgical treatment of osteosarcoma in patients without detectable metastases at the time of treatment. The HDMTX regime has been used by Jaffe and colleagues (Jaffe et al. 1974) . Vincristine was given before the methotrexate in an attempt to increase its uptake by the tumour. Adriamycin was used in another series (Cortes et al. 1974 ). Pratt et al. (1974) have reported a regime using courses of adriamycin, cyclophosphamide and HDMTX, whilst Sutow (1975) has reported his results using a regime containing vincristine, cyclophosphamide, adriamycin and melphalan. All these regimes have been associated with an improvement in recurrence-free rate, and preliminary assessment after a relatively short follow up suggests a significant improvement in survival. None of these studies have been carried out as randomized controlled trials.
However, a working party of the Medical Research Council has initiated a randomized study in the United Kingdom. An investigation of the relative merit of a regime containing vincristine, high-dose methotrexate with leucovorin rescue is compared with a regime in which this same treatment is alternated with courses of adriamycin. It is hoped to determine the efficacies of these regime,s together with an assessment of their toxicity.
Current chemotherapeutic regimes for osteogenic sarcoma, even though of considerable potential benefit, also are potentially very toxic. Much further work is needed to determine the optimal regimes for botfi adjuvant drug therapy associated with the primary treatment and also for the treatment of established metastases.
